KR20230097021A - 약학 조성물 - Google Patents

약학 조성물 Download PDF

Info

Publication number
KR20230097021A
KR20230097021A KR1020237014087A KR20237014087A KR20230097021A KR 20230097021 A KR20230097021 A KR 20230097021A KR 1020237014087 A KR1020237014087 A KR 1020237014087A KR 20237014087 A KR20237014087 A KR 20237014087A KR 20230097021 A KR20230097021 A KR 20230097021A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
acid
amorphous solid
solid dispersion
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014087A
Other languages
English (en)
Korean (ko)
Inventor
제런 왕
슌 첸
šœ 첸
지치안 펭
롱웨이 선
얀신 자오
Original Assignee
선전 파마신 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 선전 파마신 컴퍼니 리미티드 filed Critical 선전 파마신 컴퍼니 리미티드
Publication of KR20230097021A publication Critical patent/KR20230097021A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237014087A 2020-09-29 2021-09-29 약학 조성물 Pending KR20230097021A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020118608 2020-09-29
CNPCT/CN2020/118608 2020-09-29
PCT/CN2021/121695 WO2022068876A1 (en) 2020-09-29 2021-09-29 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
KR20230097021A true KR20230097021A (ko) 2023-06-30

Family

ID=80951208

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014087A Pending KR20230097021A (ko) 2020-09-29 2021-09-29 약학 조성물

Country Status (9)

Country Link
US (3) US12527793B2 (https=)
EP (1) EP4221690A4 (https=)
JP (1) JP2023543815A (https=)
KR (1) KR20230097021A (https=)
CN (1) CN116635015A (https=)
AU (1) AU2021353684A1 (https=)
CA (1) CA3193829A1 (https=)
MX (1) MX2023003556A (https=)
WO (1) WO2022068876A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
AU2023239642A1 (en) 2022-03-25 2024-11-07 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions of protac compounds and uses thereof
CN114869853A (zh) * 2022-05-25 2022-08-09 济宁医学院 一种柚皮素固体分散体及其制备方法
JP2025523707A (ja) * 2022-05-28 2025-07-23 アヴァリン ファーマ インク. ニンテダニブおよびニンテダニブの組み合わせ乾燥粉末組成物と使用
EP4642435A1 (en) * 2022-12-29 2025-11-05 Renata Pharmaceuticals (Ireland) Limited Pharmaceutical suspension of nilotinib
US12419892B2 (en) * 2023-11-08 2025-09-23 Xspray Pharma Ab Pharmaceutical compositions comprising nilotinib
WO2025146653A1 (en) * 2024-01-04 2025-07-10 Biophore India Pharmaceuticals Pvt. Ltd Process for the preparation of n- [4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxy pyrrolidin-l-yl]-5-(lh-pyrazol-3-yl) pyridine-3- carboxamide and pharmaceutically acceptable salts thereof
WO2025213381A1 (en) * 2024-04-10 2025-10-16 Hangzhou Jitai Pharmaceutical Technology Co., Ltd Neratinib-cyclodextrin composition and method for preparing same

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12625A (en) 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR100767349B1 (ko) 2006-08-01 2007-10-17 삼천당제약주식회사 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CN101185633A (zh) 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
CN101185627B (zh) 2007-12-14 2011-04-20 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼罗替尼缓释植入剂
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CN101336890A (zh) 2008-05-30 2009-01-07 济南基福医药科技有限公司 一种抗癌缓释凝胶注射剂
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
CA3152557A1 (en) * 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
IN2011CH01887A (https=) * 2011-06-02 2012-12-14
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102836159B (zh) 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
EP2802314B1 (en) 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
JP2016522182A (ja) 2013-04-24 2016-07-28 ドクター レディズ ラボラトリーズ リミテッド ニロチニブ塩酸塩の多形形態
EP2988729A1 (en) 2013-04-25 2016-03-02 Sun Pharmaceutical Industries Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
CN104367557A (zh) 2013-08-12 2015-02-25 浙江九洲药业股份有限公司 无定型药物活性成分与pvp组合物的制备方法
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
CN104274837B (zh) 2014-09-18 2017-01-11 福格森(武汉)生物科技股份有限公司 一种尼洛替尼口服制剂
CA2964198C (en) 2014-10-16 2023-03-14 Apotex Inc. Solid forms of nilotinib hydrochloride
WO2016097011A1 (en) 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising amorphous nilotinib
CN105983098B (zh) * 2015-01-30 2020-02-21 湖北生物医药产业技术研究院有限公司 用于提高难溶性的抗肿瘤药物生物利用度的固体组合物及其制备方法
EA036204B1 (ru) 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
CN106932522A (zh) * 2015-12-31 2017-07-07 上海奥博生物医药技术有限公司 一种尼罗替尼中杂质化合物i含量的测定方法
KR101770403B1 (ko) 2016-01-14 2017-08-23 중앙대학교 산학협력단 용해도가 개선된 셀레콕시브 고체분산체 및 이의 제조방법
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
EP3429589B1 (en) 2016-03-17 2022-12-14 Sun Pharmaceutical Industries Ltd Pharmaceutical composition of nilotinib
CA3041134A1 (en) 2016-10-28 2018-05-03 Apotex Inc. Novel salts of nilotinib and crystalline forms thereof
CN107320460B (zh) 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
WO2020121326A1 (en) 2018-12-13 2020-06-18 Mylan Laboratories Limited Amorphous (rac)-tramadol.hcl-celecoxib (1:1)
US11103502B2 (en) 2019-01-10 2021-08-31 Slayback Pharma Llc Pharmaceutical compositions of lurasidone
CN113573712A (zh) * 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
WO2020225738A1 (en) 2019-05-07 2020-11-12 Alembic Pharmaceuticals Limited Pharmaceutical composition comprising venetoclax
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
EP3903769A1 (en) 2020-04-30 2021-11-03 Rheinische Friedrich-Wilhelms-Universität Bonn Solid and liquisolid formulations of corallopyronin a
US20220378788A1 (en) 2020-04-30 2022-12-01 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP2023540185A (ja) 2020-09-03 2023-09-22 ニコベンチャーズ トレーディング リミテッド 組成物及び方法
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
AU2023239642A1 (en) 2022-03-25 2024-11-07 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions of protac compounds and uses thereof

Also Published As

Publication number Publication date
EP4221690A1 (en) 2023-08-09
US20230414613A1 (en) 2023-12-28
AU2021353684A1 (en) 2023-06-08
EP4221690A4 (en) 2024-10-30
CA3193829A1 (en) 2022-04-07
US12527793B2 (en) 2026-01-20
US20240226102A1 (en) 2024-07-11
US20260115192A1 (en) 2026-04-30
US12186316B2 (en) 2025-01-07
MX2023003556A (es) 2023-06-13
CN116635015A (zh) 2023-08-22
WO2022068876A1 (en) 2022-04-07
AU2021353684A9 (en) 2025-03-13
JP2023543815A (ja) 2023-10-18

Similar Documents

Publication Publication Date Title
US12527793B2 (en) Pharmaceutical compositions
KR101598747B1 (ko) 닐로티닙 또는 그의 염을 포함하는 제약 조성물
EP3125872B1 (en) Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same
RU2489149C2 (ru) Стабилизированные аморфные формы иматиниба мезилата
AU2014226292B2 (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
US20150273070A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(triflouoromethyl)phenyl] benzamide solubilized using organic acids
CN116847831A (zh) 无定形固体分散系的药物组合物及其制备方法
CN119421703A (zh) 无定形固体分散体和包含所述无定形固体分散体的药物组合物
TW202345842A (zh) Protac化合物之醫藥組合物及其用途
JP5635491B2 (ja) 固形医薬組成物
EP2359816B1 (en) Aripiprazole formulations
EP2839835B1 (en) Encapsulated formulation
HK40070844A (en) Pharmaceutical compositions comprising nilotinib
AU2012271746A1 (en) Modified release of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl) benzamide solubilized using organic acids
HK1206989B (en) Encapsulated formulation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230425

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination